But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
